Catalogue

Background
Chromogranin A is the major protein co-stored and co-released with catecholamines from secretory vesicles in adrenal medulla and postganglionic sympathetic axons. It is required for formation of catecholamine secretory vesicles in chromaffin cells and its expression may be sufficient even to induce a regulated secretory system in non-secretory cells. It is also a pro-hormone that gives rise to biologically active peptides such as the dysglycemic peptide pancreastatin, the antimicrobial peptide chromacin, the vasodilator vasostatin, and catestatin that acts to inhibit catecholamine release.

Synonyms: SP-1, Pituitary Secretory Protein I

Source

Immunogen: Synthetic peptide derived from human Chromogranin A protein

Product

Product Form: Affinity Purified

Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide

Purification Method: Antigen Immunoaffiinity Purification

Concentration: See vial for concentration

Applications
Antibody can be used for immunohistochemistry (1-3 µg/ml) and Western blotting (1-2 µg/ml). Optimal concentration should be evaluated by serial dilutions.

Functional Analysis: Western Blotting

Positive Control: Human small bowel tissue

Storage
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Product Stability: See expiration date on vial

Shipping Conditions: Ship at ambient temperature, freeze upon arrival

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but our company accepts no liability for any inaccuracies or omissions in this information.

References
1. Konecki, D.S., et al. ‘The primary structure of human chromogranin A and pancreastatin’ J. Biol. Chem., 262, 17026-17030 (1987) 2. Pasqua, T., et al. ‘Full-length human chromogranin-A cardioactivity: myocardial, coronary, and stimulus-induced processing evidence in normotensive and hypertensive male rat hearts.’ Endocrinology, 154, 3353-3365 (2013) 3. Chen, Y., et al. ‘Naturally occurring genetic variants in human chromogranin A (CHGA) associated with hypertension as well as hypertensive renal disease.’ Cell Mol. Neurobiol., 30, 1395-1400 (2010) 4. Mahapatra, N.R., et al. ‘Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog.’ J. Clin. Invest., 115, 1942-1952 (2005) 5. Mahata, S.K., et al. ‘Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist.’ J. Clin. Invest., 100, 1623-1633 (1997).

Protein Reference(s)

Database Name: SwissProt

Accession Number: P10645

Species Accession: Human

Safety Datasheet(s) for this product: